The burden of cardiovascular diseases (CVD) is huge in the UK. Approximately 7.6 million people in the UK are affected by CVD, which accounts for approximately 164,000 deaths per year. COVID-19 has substantially impacted CVD management across the board, including prevention, referrals, diagnosis, treatment and rehabilitation. In particular, health checks have dropped by 97%, which is a significant indicator of a decrease in screening and prevention, and consequently, to the initiation of preventative medicines, especially statins. While the shift to virtual appointments has been celebrated, in-person primary care attendance has decreased by 42%, which has significant implications on procedures that traditionally need in-person presence, such as measuring blood pressure and performing pulse checks. CVD referrals have also dropped by 43% which means that patients are not being referred for further specialist opinion. Indeed, this disruption has affected CVD services across the pathway, with a 19% to 45% reduction in elective procedures, a 41% to 44% drop in elective imaging, a 53% decrease in emergency admissions, and 36% drop in cardiac rehabilitation group exercise.